Akihiro Shimozato1, Makoto Sasaki1, Naotaka Ogasawara1, Yasushi Funaki1, Masahide Ebi1, Chiho Goto2, Satoshi Koikeda3, Takashi Joh4, Kunio Kasugai1. 1. Department of Gastroenterology, Aichi Medical University School of Medicine, Nagakute, Japan. 2. Department of Health and Nutrition, Faculty of Health and Human Life, Nagoya Bunri University, Inazawa, Japan. 3. Department of Frontier Research, Amano Enzyme Inc., Kakamigahara, Japan. 4. Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Abstract
BACKGROUND: Recent studies have highlighted the relationship between gut microbiota and bowel movements. OBJECTIVE: We aimed to evaluate transglucosidase treatment efficacy for bowel movements in patients with type 2 diabetes mellitus and to clarify the relationship between bowel movements, dietary habits, gut microbiota and fecal short-chain fatty acids. METHODS: In this randomized double-blind, placebo-controlled study, 66 patients receivedplacebo or transglucosidase (300 or 900 mg/day) orally, for 12 weeks. Fecal bacterial communities and short-chain fatty acids were analyzed before and after the treatment. RESULTS:Transglucosidase treatment significantly (p < 0.05) affected fecal microbiota (Prevotella spp., Bacteroides spp., Bifidobacterium spp., and Clostridium subcluster XIVa) and fecal short-chain fatty acid (acetate, valerate, succinate and lactate) content. Clostridium cluster IV, Clostridium subcluster XIVa, Clostridium cluster XVIII and fecal pH increased significantly and order Lactobacillales decreased in patients with bowel movement disorder compared with controls. Transglucosidase treatment significantly improved bowel movements compared with placebo treatment (46.2%, 95% confidence interval: 19.2-74.9% vs. 0%, 95% confidence interval: 0-33.6%, p < 0.05). This effect was not observed in patients without bowel movement disorder. CONCLUSION:Patients with bowel movement disorder suffer from gut dysbiosis. Transglucosidase treatment alleviates bowel movement disorder symptoms in type 2 diabetes mellitus patients by increasing fecal acetate level.
RCT Entities:
BACKGROUND: Recent studies have highlighted the relationship between gut microbiota and bowel movements. OBJECTIVE: We aimed to evaluate transglucosidase treatment efficacy for bowel movements in patients with type 2 diabetes mellitus and to clarify the relationship between bowel movements, dietary habits, gut microbiota and fecal short-chain fatty acids. METHODS: In this randomized double-blind, placebo-controlled study, 66 patients received placebo or transglucosidase (300 or 900 mg/day) orally, for 12 weeks. Fecal bacterial communities and short-chain fatty acids were analyzed before and after the treatment. RESULTS: Transglucosidase treatment significantly (p < 0.05) affected fecal microbiota (Prevotella spp., Bacteroides spp., Bifidobacterium spp., and Clostridium subcluster XIVa) and fecal short-chain fatty acid (acetate, valerate, succinate and lactate) content. Clostridium cluster IV, Clostridium subcluster XIVa, Clostridium cluster XVIII and fecal pH increased significantly and order Lactobacillales decreased in patients with bowel movement disorder compared with controls. Transglucosidase treatment significantly improved bowel movements compared with placebo treatment (46.2%, 95% confidence interval: 19.2-74.9% vs. 0%, 95% confidence interval: 0-33.6%, p < 0.05). This effect was not observed in patients without bowel movement disorder. CONCLUSION:Patients with bowel movement disorder suffer from gut dysbiosis. Transglucosidase treatment alleviates bowel movement disorder symptoms in type 2 diabetes mellituspatients by increasing fecal acetate level.
Authors: Peter J Turnbaugh; Ruth E Ley; Michael A Mahowald; Vincent Magrini; Elaine R Mardis; Jeffrey I Gordon Journal: Nature Date: 2006-12-21 Impact factor: 49.962
Authors: Rodolphe Soret; Julien Chevalier; Pierre De Coppet; Guillaume Poupeau; Pascal Derkinderen; Jean Pierre Segain; Michel Neunlist Journal: Gastroenterology Date: 2010-02-10 Impact factor: 22.682
Authors: M Sasaki; K Imaeda; N Okayama; T Mizuno; H Kataoka; T Kamiya; E Kubota; N Ogasawara; Y Funaki; M Mizuno; A Iida; C Goto; S Koikeda; K Kasugai; T Joh Journal: Diabetes Obes Metab Date: 2011-12-27 Impact factor: 6.577
Authors: Nadja Larsen; Finn K Vogensen; Frans W J van den Berg; Dennis Sandris Nielsen; Anne Sofie Andreasen; Bente K Pedersen; Waleed Abu Al-Soud; Søren J Sørensen; Lars H Hansen; Mogens Jakobsen Journal: PLoS One Date: 2010-02-05 Impact factor: 3.240